Table 1.
FDA-approved oral kinase inhibitors are listed with indications in parentheses.
| FDA Approved Year (New) | Agent (Indication) |
|---|---|
| 2001 (1) | Imatinib (CML) |
| 2002 (0) | Imatinib (advanced GIST) |
| 2003 (1) | Gefitinib |
| 2004 (1) | Erlotinib (lung) |
| 2005 (1) | Erlotinib (pancreas) |
| Sorafenib (RCC) | |
| 2006 (2) | Dasatinib (2nd line) |
| Sunitinib (RCC, GIST) | |
| 2007 (2) | Lapatinib, Nilotinib (2nd line) |
| Sorafenib (HCC) | |
| 2008 (0) | Imatinib (adjuvant GIST) |
| 2009 (1) | Pazopanib (RCC) |
| 2010 (0) | Dasatinib (1st line) |
| Nilotinib (1st line) | |
| 2011 (4) | Crizotinib |
| Ruxolitinib | |
| Sunitinib (pNET) | |
| Vandetanib | |
| Vemurafenib | |
| 2012 (4) | Axitinib |
| Bosutinib | |
| Cabozantinib | |
| Pazopanib (sarcoma) | |
| Regorafenib (CRC) | |
| Vismodegib | |
| Ponatinib | |
| 2013 (0) | Regorafenib (GIST) |
| Erlotinib (1st line, EFGR mutated) |
Abbreviations: CML, chronic myelogenous leukemia; CRC, colorectal carcinoma; GIST, gastrointestinal stromal tumor; RCC, renal cell carcinoma; HCC, hepatocellular carcinoma; pNET, pancreatic neuroendocrine tumor; EGFR, epithelial growth factor receptor.